COMMUNIQUÉS West-GlobeNewswire

Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
27/05/2026
Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with Dalton Tx ’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS [...]
Remarcate Limited Liability Company Expands Into U.S. Market to Support Hispanic Healthcare Providers With AI-Driven Patient Acquisition Systems
27/05/2026
WESLEY CHAPEL, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Remarcate Limited Liability Company, a Florida-based healthcare marketing and patient acquisition company, announced the expansion of its operations into the United [...]
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
27/05/2026
Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO—a certified algorithm developed by the [...]
argenx to Present at Upcoming Investor Conferences
27/05/2026
May 27, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
27/05/2026
SHANGHAI, May 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Vireo Growth Inc. Exercises Option to Purchase New York Facility from Innovative Industrial Properties
27/05/2026
MINNEAPOLIS, May 26, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that its subsidiary, 256 County Route 117 Perth LLC (the “Buyer”), completed the [...]
Inventiva publie ses informations financières du premier trimestre 2026¹
26/05/2026
Trésorerie et équivalents de trésorerie de 75 millions d'euros, et 121,5millions d'euros de dépôts à court terme 2025 2 Daix (France), New York City (New York, United States), le 26 mai 2026 – Inventiva (Euronext Paris [...]
Inventiva Reports 2026 First Quarter Financial Information¹
26/05/2026
Cash and cash equivalents at €75.0 million, and €121.5 million in short-term deposits 2 Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or [...]
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
26/05/2026
WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Dianthus Therapeutics to Participate in Two Investor Conferences
26/05/2026
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
26/05/2026
Webcast to be held Wednesday, May 27th at 8:00 a.m. ET SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, [...]
Lakefront Receives Transparency Notification from Bank of America
26/05/2026
Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transparency [...]
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
26/05/2026
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 [...]
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
26/05/2026
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today [...]
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
26/05/2026
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
OrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
26/05/2026
WARSAW, Ind., May 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
26/05/2026
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic [...]
Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
26/05/2026
Drs. Sang-Won Lee and Jaewoo Kang to share early insights from Seer's 20,000-sample collaboration with Korea University in breakfast symposium on AI-driven multi-cancer screening REDWOOD CITY, Calif., May 26, 2026 ( [...]
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
26/05/2026
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data [...]

Pages